Acoramidis Cuts Clinical Worsening by 34% vs Tafamidis in First Real-World Comparison
BBIO sits 42% above its 52-week low of $48.78.
Summary
BridgeBio published the first peer-reviewed real-world comparative study of acoramidis versus tafamidis in ATTR-CM, showing a 34% reduction in composite clinical worsening (HR 0.66, p=0.046) and a 43% reduction in diuretic intensification (HR 0.57, p=0.021). The analysis used U.S. claims data from 170 acoramidis and 448 tafamidis patients with a mean follow-up of 4.6 months. This is the first head-to-head real-world evidence differentiating the two approved TTR stabilizers, potentially influencing frontline treatment decisions and switching. The data build on the Phase 3 ATTRibute-CM results presented at ESC in August, but this is a distinct real-world dataset with new comparative outcomes. An independent EHR-based real-world study is expected at an upcoming 2026 medical meeting, which could further validate these findings.
At the time of this announcement, BBIO was trading at $69.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.